27 research outputs found
Whole exome sequencing links dental tumor to an autosomal-dominant mutation in ANO5 gene associated with gnathodiaphyseal dysplasia and muscle dystrophies
Tumors of the jaws may represent different human disorders and frequently associate with pathologic bone fractures. In this report, we analyzed two affected siblings from a family of Russian origin, with a history of dental tumors of the jaws, in correspondence to original clinical diagnosis of cementoma consistent with gigantiform cementoma (GC, OMIM: 137575). Whole exome sequencing revealed the heterozygous missense mutation c.1067G \u3e A (p.Cys356Tyr) in ANO5 gene in these patients. To date, autosomal-dominant mutations have been described in the ANO5 gene for gnathodiaphyseal dysplasia (GDD, OMIM: 166260), and multiple recessive mutations have been described in the gene for muscle dystrophies (OMIM: 613319, 611307); the same amino acid (Cys) at the position 356 is mutated in GDD. These genetic data and similar clinical phenotypes demonstrate that the GC and GDD likely represent the same type of bone pathology. Our data illustrate the significance of mutations in single amino-acid position for particular bone tissue pathology. Modifying role of genetic variations in another gene on the severity of the monogenic trait pathology is also suggested. Finally, we propose the model explaining the tissue-specific manifestation of clinically distant bone and muscle diseases linked to mutations in one gene
Perissodactyl diversities and responses to climate changes as reflected by dental homogeneity during the Cenozoic in Asia
Неинвазивные методы молекулярной диагностики и клинического наблюдения и подходы к подбору персональной терапии при высокозлокачественных диффузных глиомах ствола мозга
The purpose of the study was to summarize and analyze modern data about non-invasive methods of molecular diagnosis and approaches to the personalized therapy of diffuse midline glioma (DMG). Material and Methods. The search and analysis of publications was carried out using Google Scholar, Pubmed, Elsevier, Web of Science, Elibrary systems. The review includes publications published from 2011 to 2022. Of the 102 articles found, 59 were used to write the review. Results. In this review, we discuss the spectrum of somatic driver mutations present in DMG tumor cells and their relationship with the sensitivity of tumor cells to certain types of therapy - a pharmacogenetic approach to the selection of individual treatments (targeted therapy). We provide examples of new methods of targeted therapy for DMG, which are currently at the stage of preclinical laboratory development. Also, we discuss examples of the use of 3D cell cultures for the development of targeted therapies, including the use of perfusion systems. The review describes the methods of analysis of liquid biopsy, which allow the detection of tumor-specific biomarkers in the non-invasive diagnosis of DMG, including a number of methods that have not yet been tested in the clinic. The following is a list of tumor-specific biomarkers for diagnosing, monitoring, and selecting targeted therapy for DMG. Finally, we discuss the possibility of implementing these methods in the clinic and present the results of several clinical trials. Conclusion. In oncology, new methods of molecular genetics, such as analysis of liquid biopsy, allow diagnosis and monitoring of treatment in cases where classical methods that require tissue sampling are not applicable (for example, the analysis of genetically heterogeneous tumors and tumors of surgically inaccessible localization). These tumors include DMG, a primary brain tumor most common in children. The available data confirm the relevance of the search for new specific tumor biomarkers, as well as targets for targeted therapy of the paediatric-type diffuse gliomas.Цель исследования - обобщение и анализ современных данных о неинвазивной молекулярной диагностике и соответствующих подходах к персонализированной терапии высокозлокачественных диффузных глиом ствола мозга (ДГСМ). Материал и методы. Поиск соответствующих источников производился в системах Google Scholar, Pubmed, Elsevier, Web of Science, Elibrary. В обзор включены публикации с 2011 по 2022 г. Из 102 найденных статей 59 были использованы для написания обзора. Результаты. В обзоре рассмотрены спектр соматических драйверных мутаций, присутствующих в опухолевых клетках ДГСМ, и их связь с чувствительностью опухолевых клеток к определенным видам терапии - фармакогенетический подход к подбору индивидуальных методов лечения (таргетная терапия). Обсуждаются новые методы таргетной терапии ДГСМ, находящиеся на стадии доклинической лабораторной разработки. Рассмотрены примеры использования 3D-клеточных культур для разработки таргетной терапии, в том числе с применением перфузионных систем. Описаны методы анализа жидкостной биопсии, позволяющие обнаружить опухоль-специфичные биомаркеры при неинвазивной диагностике ДГСМ, в том числе ряд методов, еще не протестированных в клинике. Приведен список опухоль-специфичных биомаркеров для диагностики, мониторинга и выбора таргетной терапии ДГСМ. В заключение обсуждается возможность внедрения данных методов в клинику, с представлением результатов нескольких клинических испытаний. Заключение. В онкологии новые методы молекулярной генетики, такие как анализ жидкостной биопсии, позволяют производить диагностику и мониторинг лечения в случаях, когда классические методы, требующие забора ткани, оказываются не применимы (к примеру, анализ генетически гетерогенных опухолей и опухолей хирургически недоступной локализации). К таким опухолям относится ДГСМ - первичная опухоль головного мозга, наиболее часто встречающаяся у детей. Имеющиеся данные подтверждают актуальность поиска новых специфических опухолевых биомаркеров, а также мишеней для таргетной терапии детских диффузных глиом
The matrix-dependent 3D spheroid model of the migration of non-small cell lung cancer: a step towards a rapid automated screening
In vitro 3D cell culture systems utilizing multicellular tumor spheroids (MCTS) are widely used in translational oncology, including for studying cell migration and in personalized therapy. However, early stages of cellular migration from MCTS and cross-talk between spheroids are overlooked, which was addressed in the current study. Here, we investigated cell migration from MCTS derived from human non-small cell lung cancer (NSCLC) cell line A549 cultured on different substrates, collagen gel or plastic, at different time points. We found that migration starts at 4–16 h time points after the seeding and its speed is substrate-dependent. We also demonstrated that co-culture of two NSCLC-derived MCTS on collagen gel, but not on plastic, facilitates cell migration compared with single MTCS. This finding should be considered when designing MCTS-based functional assays for personalized therapeutic approach and drug screenings. Overall, our work characterizes the in vitro 3D cell culture model resembling NSCLC cell migration from the clusters of CTCs into surgical wound, and describes microscopy-based tools and approaches for image data analysis with a potential for further automation. These tools and approaches also might be used to predict patterns of CTCs migration based on ex vivo analysis of patient biopsy in a 3D culture system
32nd Congress of the ESP and XXXIII International Congress of the IAP (vol 477, pg S1, 2020)
Whole-genome sequencing identifies a novel ABCB7 gene mutation for X-linked congenital cerebellar ataxia in a large family of Mongolian ancestry
X-linked congenital cerebellar ataxia is a heterogeneous nonprogressive neurodevelopmental disorder with onset in early childhood. We searched for a genetic cause of this condition, previously reported in a Buryat pedigree of Mongolian ancestry from southeastern Russia. Using whole-genome sequencing on Illumina HiSeq 2000 platform, we found a missense mutation in the ABCB7 (ABC-binding cassette transporter B7) gene, encoding a mitochondrial transporter, involved in heme synthesis and previously associated with sideroblastic anemia and ataxia. The mutation resulting in a substitution of a highly conserved glycine to serine in position 682 is apparently a major causative factor of the cerebellar hypoplasia/atrophy found in affected individuals of a Buryat family who had no evidence of sideroblastic anemia. Moreover, in these affected men we also found the genetic defects in two other genes closely linked to ABCB7 on chromosome X: a deletion of a genomic region harboring the second exon of copper-transporter gene (ATP7A) and a complete deletion of PGAM4 (phosphoglycerate mutase family member 4) retrogene located in the intronic region of the ATP7A gene. Despite the deletion, eliminating the first of six metal-binding domains in ATP7A, no signs for Menkes disease or occipital horn syndrome associated with ATP7A mutations were found in male carriers. The role of the PGAM4 gene has been previously implicated in human reproduction, but our data indicate that its complete loss does not disrupt male fertility. Our finding links cerebellar pathology to the genetic defect in ABCB7 and ATP7A structural variant inherited as X-linked trait, and further reveals the genetic heterogeneity of X-linked cerebellar disorders